Based on our results, patients with stage B3 thymoma appears to be the best candidates for such a strategy because of the high expression of PD-L1, but some thymic carcinomas with PD-L1 expression on epithelial or even immune cells may also be concerned. This evidence concerns the gene CD274 and thymoma.